Gaurav Puppalwar

No ORCID on file · 1 paper in corpus · active 2026

Study types

  • rct 1

Condition tags

  • endometriosis 1
rct 2026
Single-Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non-Pregnant, Non-Lactating Premenopausal Female Subjects Under Fasting Conditions
Clinical pharmacology in drug development ·doi:10.1002/cpdd.70053

Elagolix is a short-acting oral gonadotropin-releasing hormone antagonist utilized for treating endometriosis-associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical d…